Wahlén A, Westerlund D, Wåhlin-Boll E, Melander A
Drug Nutr Interact. 1983;2(3):175-81.
The possible influence of concomitant food intake on the bioavailability of the novel antidepressant zimeldine and its active metabolite norzimeldine was assessed in ten healthy female volunteers, who ingested a single dose of 200 mg zimeldine on an empty stomach and together with a standardized breakfast of 1 840 kJ. The plasma concentrations of zimeldine and norzimeldine were measured by a selective modern liquid chromatographic technique. Neither the peak concentration nor time to reach peak concentration nor elimination half-life nor the total area under the curve (AUC) of zimeldine was affected by concomitant food intake. For norzimeldine, the peak concentration showed a 10% reduction, but there was no change in any other parameter. Thus, the bioavailability of zimeldine and of its active metabolite norzimeldine is unaffected by food intake, suggesting that the drug need not be taken in a strictly defined relation to meals.
在10名健康女性志愿者中评估了同时摄入食物对新型抗抑郁药齐美利定及其活性代谢产物去甲齐美利定生物利用度的可能影响。这些志愿者在空腹状态下以及与一份能量为1840千焦的标准早餐一起服用了单剂量200毫克的齐美利定。采用选择性现代液相色谱技术测定齐美利定和去甲齐美利定的血浆浓度。同时摄入食物对齐美利定的峰浓度、达峰时间、消除半衰期以及曲线下总面积（AUC）均无影响。对于去甲齐美利定，峰浓度降低了10%，但其他参数均无变化。因此，齐美利定及其活性代谢产物去甲齐美利定的生物利用度不受食物摄入的影响，这表明该药物无需严格按照与进餐的特定关系服用。
